Oslo, Norway, February 14, 2022 - Nykode Therapeutics AS (Euronext Growth
(Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the
discovery and development of vaccines and novel immunotherapies, today announced
that its Chief Executive Officer, Michael Engsig, and Chief Innovation and
Strategy Officer, Agnete Fredriksen, will present and provide a corporate update
at the SVB Leerink 2022 Global Healthcare Conference on February 18, 2022 at
2.00 p.m. CET/ 8.00 a.m. EST and are available for 1:1 investor meetings. 

An updated corporate presentation will be available in the Investors section of
the Company's website at 7:00 a.m. CET on February 18, 2022 at
www.nykode.com/investors. The live and archived webcast of the presentation can
be accessed in the Investors section of the Company's website
www.nykode.com/investors/financial-reports-and-presentations.  


Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer